White Paper
Rare Diseases vs. Rare Tumor Types
Rare diseases and rare tumor types are often treated as one category, but they diverge in nearly every dimension that matters commercially and clinically — how they're defined, diagnosed, regulated, and managed. This white paper compares both across epidemiology, diagnostic pathways, molecular basis, regulatory frameworks, and clinical management, drawing on published literature and expert perspective from NIH, Dana-Farber, FDA, and EURORDIS leadership. The analysis closes with six policy recommendations for closing the gaps between these two parallel worlds.
What’s Inside
- How rare disease and rare tumor definitions differ — and where the two categories overlap
- Why rare tumor patients get diagnosed fast but face high subtype misclassification, while rare disease patients face 5–7 year diagnostic odysseys
- How orphan drug frameworks and tumor-agnostic approvals create different regulatory paths for each category
- Six policy recommendations for closing the diagnostic, regulatory, and infrastructure gaps between the two fields
